Insulin
8 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
8
Ongoing
1
Recruiting
1
Completed
4
Sites
31
Countries
2
Endpoints
125
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 125 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 21 of 125 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
9
4
3
3
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
8 of 8
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT01767909The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) | Insulin Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Ph 2/3 | Completed | 25 | Dec 2018 | 7 | results |
| SL120Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120) | Insulin, Insulin detemir Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Ph 2 | Completed | 2 | Mar 2015 | - | results |
| SNIFF 120SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days) | Insulin Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Ph 2 | Completed | 1 | Dec 2011 | 4 | |
| NCT05081219SNIFF - Combo INI+EMPA Trial | Empagliflozin, Insulin Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Ph 2 | Completed | 1 | Sep 2024 | 53 | results |
| NCT06072963COMMETS- Combination MCI Metabolic Syndrome | Insulin, Semaglutide Alzheimer’s disease, MCI / preclinical Alzheimer’s | MoCA ≤27 | Ph 2 | Recruiting | 1 | Dec 2027 | 58 | |
| NCT04115384Intranasal Insulin in Frontotemporal Dementia (FTD) | Insulin Frontotemporal dementia | MMSE ≥18 | Ph 2 | Terminated | 1 | Feb 2020 | - | results |
| NCT05006599SNIFF - 3-Week Aptar CPS Device | Insulin Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Ph 2 | Withdrawn | 0 | May 2029 | 52 | |
| Memori³Investigating Brain Insulin Resistance in Alzheimer Disease with IntraNasal Insulin : a Multimodal Neuroimaging Study | Insulin Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Not applicable | Withdrawn | 0 | Mar 2026 | 16 |
Showing 1-8 of 8 trials